Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

  • Invest New Drugs. 2017 Jun;35(3):397. doi: 10.1007/s10637-017-0455-y.
S Fu  1 ,  H Hirte  2 ,  S Welch  3 ,  T T Ilenchuk  4 ,  T Lutes  4 ,  C Rice  4 ,  N Fields  5 ,  A Nemet  6 ,  D Dugourd  4 ,  S Piha-Paul  1 ,  V Subbiah  1 ,  L Liu  1 ,  J Gong  1 ,  D Hong  1 ,  J M Stewart  7
Affiliations
  • 1. Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.
  • 2. Juravinski Cancer Centre, Hamilton, ON, Canada.
  • 3. London Health Sciences Centre, London, ON, Canada.
  • 4. Soricimed Biopharma Inc., Moncton, NB, Canada.
  • 5. Sagecon Inc., Oakville, ON, Canada.
  • 6. CLINSIG Research Consulting Inc., Brampton, ON, Canada.
  • 7. Soricimed Biopharma Inc., Moncton, NB, Canada. [email protected].
PMID: 28389981 DOI: 10.1007/s10637-017-0455-y
Products